TimesSquare Capital Management LLC Purchases 4,244 Shares of Repligen Corporation $RGEN

TimesSquare Capital Management LLC increased its position in Repligen Corporation (NASDAQ:RGEN) by 1.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 240,231 shares of the biotechnology company’s stock after purchasing an additional 4,244 shares during the period. TimesSquare Capital Management LLC owned approximately 0.43% of Repligen worth $29,880,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Twin Tree Management LP acquired a new position in shares of Repligen during the first quarter valued at about $29,000. Hantz Financial Services Inc. boosted its stake in Repligen by 2,663.6% during the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 293 shares during the last quarter. Signaturefd LLC boosted its stake in Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 128 shares during the last quarter. Center for Financial Planning Inc. increased its holdings in Repligen by 34.2% during the 2nd quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 126 shares in the last quarter. Finally, AlphaQuest LLC purchased a new stake in shares of Repligen in the second quarter worth approximately $104,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Up 5.3%

RGEN stock opened at $153.44 on Wednesday. The stock has a 50-day simple moving average of $139.04 and a two-hundred day simple moving average of $129.37. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The firm has a market capitalization of $8.64 billion, a PE ratio of 7,675.84, a PEG ratio of 3.32 and a beta of 1.14. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The firm had revenue of $188.80 million for the quarter, compared to the consensus estimate of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The company’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, equities analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on RGEN shares. Evercore ISI upped their price objective on Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Canaccord Genuity Group upped their price target on Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Wednesday, October 29th. HC Wainwright reiterated a “buy” rating and set a $180.00 price target on shares of Repligen in a research note on Wednesday, September 3rd. Weiss Ratings restated a “sell (d)” rating on shares of Repligen in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $205.00 price objective on shares of Repligen in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $173.85.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.